Fenofibrate increases the expression of high mobility group AT-hook 2 (HMGA2) gene and induces adipocyte differentiation of orbital fibroblasts from Graves' ophthalmopathy

Journal of Molecular Endocrinology

Volumn 33, Issue 1, 2004, Pages 133-143

  Pasquali, Daniela ^a   Pierantoni, Giovanna Maria ^b   Fusco, Alfredo ^b   Staibano, Stefania ^b   Colantuoni, Vittorio ^b,c   De Bellis, Annamaria ^a   Bellastella, Antonio ^a   Sinisi, Antonio Agostino ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF SANNIO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; FENOFIBRATE; HIGH MOBILITY GROUP A2 PROTEIN; LEPTIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; THYROTROPIN RECEPTOR;

ADIPOCYTE; ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENDOCRINE OPHTHALMOPATHY; FEMALE; FIBROBLAST CULTURE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE;

ADIPOCYTES; BASE SEQUENCE; CELL DIFFERENTIATION; DNA PRIMERS; FIBROBLASTS; GENE EXPRESSION REGULATION; GRAVES DISEASE; HMGA2 PROTEIN; HUMANS; ORBIT; PPAR ALPHA; PPAR GAMMA; PROCETOFEN; RECEPTORS, THYROTROPIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 4444235503     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/jme.0.0330133     Document Type: Article

References (35)

1. Anand A & Chada K 2000 In vivo modulation of Hmgic reduces obesity. Nature Genetics 24 377-380.
2. Arlotta P, Tai AK, Manfioletti G, Clifford C, Jay G & Ono SJ 2000 Transgenic mice expressing a truncated form of the high mobility group I-C protein develop adiposity and an abnormally high prevalence of lipomas. Journal of Biological Chemistry 275 14394-14400.
3. Bahn RS, Dutton CM, Natt N, Joba W, Spitzweg C, Heufelder AE 1998 Thyrotropin receptor expression in Graves' orbital adipose/connective tissues; potential autoantigen in Graves' ophthalmopathy. Journal of Clinical Endocrinology and Metabolism 83 998-1002.
4. Bandiera A, Bonifacio D, Manfioletti G, Mantovani F, Rustighi A, Zanconati F, Fusco A, Di Bonito L & Giancotti V 1998 Expression of HMGI(Y) proteins in squamous intraepithelial and invasive lesions of the uterine cervix. Cancer Research 58 426-431.
5. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A & Evans RM 1999 PPAR gamma is required for placental, cardiac, and adipose tissue development. Molecular Cell 4 585-595.
6. Basolo F, Giannini R, Toniolo A, Casalone R, Nikiforova M, Pacini F, Elisei R, Miccoli P, Berti P, Faviana P et al. 2002 Establishment of a non tumorigenic papillary thyroid cell line (FB-2) carrying the ret/ptc1 rearrangement. International Journal of Cancer 97 608-614.
7. Battista S, Fidanza V, Fedele M, Klein-Szanto AJ, Outwater E, Brunner H, Santoro M, Croce CM & Fusco A 1999 The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. Cancer Research 59 4793-4797.
8. Bost F, Caron L, Marchetti I, Dani C, Le Marchand-Brustel Y & Binetruy B 2002 Retinoic acid activation of the ERK pathway is required for embryonic stem cell commitment into the adipocyte lineage. Biochemical Journal 361 621-627.
9. Brandes R, Arad R & Bar-Tana J 1986 Adipose conversion of cultured rat primary preadipocytes by hypolipidemic drugs. Biochimica et Biophysica Acta 877 314-321.
10. Chiappetta G, Bandiera A, Berlingieri MT, Visconti R, Manfioletti G, Battista S, Martinez-Tello FJ, Santoro M, Giancotti V & Fusco A 1995 The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasms. Oncogene 10 1307-1314.
11. Delerive P, Fruchart JC & Staels B 2001 Peroxisome proliferator-activated receptors in inflammation control. Journal of Endocrinology 169 453-459.
12. Desvergne B & Wahli W 1999 Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Review 20 649-688.
13. Falvo JV, Thanos D & Maniatis T 1995 Reversal of intrinsic DNA bends in the IFN beta gene enhancer by transcription factors and the architectural protein HMG I(Y). Cell 83 1101-1111.
14. Fedele M, Bandiera A, Chiappetta G, Battista S, Viglietto G, Manfioletti G, Casamassimi A, Santoro M, Giancotti V & Fusco A 1996 Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. Cancer Research 56 1896-1901.
15. Feliciello A, Porcellini A, Ciullo L, Bonavolonta G, Avvedimento E & Fenzi G 1993 Expression of thyrotropin receptor mRNA in healthy and Graves' disease retro-orbital tissue. Lancet 342 337-338.
16. Johnson KR, Lehn DA & Reeves R 1989 Alternative processing of mRNAs encoding mammalian chromosomal high-mobility-group proteins HMG-I and HMG-Y. Molecular and Cellular Biology 9 2114-2123.
17. Kopelovich L, Fay JR, Glazer RI & Crowell JA 2002 Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents. Molecular Cancer Therapy 1 357-363.
18. Koumas L, Smith TJ, & Phipps RP 2002 Fibroblast subsets in the human orbit: Thy-1+ and Thy-1 - subpopulations exhibit distinct phenotypes. European Journal of Immunology 32 477-485.
19. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T et al. 1999 PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Molecular Cell 4 597-609.
20. Manfioletti G, Giancotti V, Bandiera A, Buratti E, Sautiere P, Cary P, Crane-Robinson C, Coles B & Goodwin GH 1991 cDNA cloning of the HMGI-C phosphoprotein, a nuclear protein associated with neoplastic and undifferentiated phenotypes. Nucleic Acids Research 19 6793-6797.
21. Pasquali D, Rossi V, Prezioso D, Gentile V, Colantuoni V, Lotti T, Bellastella A & Sinisi AA 1999 Changes in tissue transglutaminase activity and expression during retinoic acid-induced growth arrest and apoptosis in primary cultures of human epithelial prostate cells. Journal of Clinical Endocrinology and Metabolism 84 1463-1469.
22. Pasquali D, Vassallo P, Esposito D, Bonavolontà G, Bellastella A & Sinisi AA 2000 Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves' ophthalmopathy. Journal of Molecular Endocrinology 25 63-71.
23. Pasquali D, Notaro A, Bonavolontà G, Vassallo P, Bellastella A & Sinisi AA 2002 Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves' disease. Journal of Clinical Endocrinology and Metabolism 87 5125-5129.
24. Pasquali D, Bellastella A, Colantuoni V, Vassallo P, Bonavolontà G, Rossi V, Notaro A & Sinisi AA 2003 All-trans-retinoic acid and n-(4-hydroxyphenyl)-retinamide induced growth arrest and apoptosis in orbital fibroblasts in Graves' disease. Metabolism 52 1387-1392.
25. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM & Mortensen RM 1999 PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Molecular Cell 4 611-617.
26. Santulli B, Kazmierczak B, Napolitano R, Caliendo I, Chiappetta G, Rippe V, Bullerdiek J & Fusco A 2000 A 12q13 translocation involving the HMGI-C gene in Richter transformation of a chronic lymphocytic leukemia. Cancer Genetic and Cytogenetic 119 70-73.
27. Shao D & Lazar MA 1997 Peroxisome proliferator activated receptor gamma, CCAAT/enhancer-binding protein alpha, and cell cycle status regulate the commitment to adipocyte differentiation. Journal of Biological Chemistry 272 21473-21478.
28. Smith TJ 2002 Orbital fibroblasts exhibit a novel pattern of responses to proinflammatory cytokines: potential basis for the pathogenesis of thyroid-associated ophthalmopathy. Thyroid 12 197-203.
29. Sorisky A, Pardasani D, Gagnon A & Smith TJ 1996 Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture. Journal of Clinical Endocrinology and Metabolism 81 3428-3431.
30. Starkey K, Heufelder A, Baker G, Joba W, Evans M, Davies S & Ludgate M 2003 Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use? Journal of Clinical Endocrinology and Metabolism 88 55-59.
31. Tontonoz P, Hu E & Spiegelman BM 1994 Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79 1147-1156.
32. Valyasevi RW, Harteneck DA, Dutton CM & Bahn RS 2002 Stimulation of adipogenesis, peroxisome proliferator-activated receptor? (PPARγ), and thyrotropin receptor by PPARγ agonist in human orbital preadipocyte fibroblasts. Journal of Clinical Endocrinology and Metabolism 87 2352-2358.
33. Woods SC, Seeley RJ, Porte D Jr & Schwartz MW 1998 Signals that regulate food intake and energy homeostasis. Science 280 1378-1383.
34. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L & Friedman JM 1994 Positional cloning of the mouse obese gene and its human homologue. Nature 372 425-432.
35. Zhou X, Benson KF, Ashar HR & Chada K 1995 Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 376 771-774.